An Introduction to Stroke
Most strokes (85%) are caused by acute ischaemia due to blockage of a cerebral artery, leading to loss of oxygenation in downstream brain tissue, and ultimately causing neuronal cell death and irreversible neurological damage. The remainder are haemorrhagic strokes, caused by intracerebral or subarachnoid haemorrhage. Treatment of ischaemic stroke has been transformed by advances in imaging technology, as well as the emergence of thrombolytics and subsequent mechanical thrombectomy, sometimes facilitating complete recovery. Increasingly, oral anticoagulants are preventing stroke in patients with atrial fibrillation. Therapies targeting neuroinflammation after brain ischaemia (e.g. transplantation of mesenchymal stem cells) are also emerging as potentially useful.
Browse our gallery of video highlights and short articles from the conference hub, providing latest expert insights from major conferences and peer-reviewed articles from the journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Anabolic Androgenic Steroid Abuse and Cerebral Venous Thrombosis—A Case Report
US Neurology. 2020;16(2):120–2 DOI: https://doi.org/10.17925/USN.2020.16.2.120
Cerebral venous thrombosis (CVT) is a rare condition.1–3 While thrombophilias, contraceptive pill, hormonal replacement therapy, and neoplasms are well-established predisposing factors, steroid use is a less-common possible risk factor, particularly with regard to anabolic androgenic steroids (AAS).1–4 We intend to describe what is known about AAS and present a case of CVT associated with AAS use […]
Vida Demarin, CONy 2020 – Statins for Stroke Prevention in Older Generations
Vida Demarin (International Institute for Brain Health, Zagreb, Croatia) kindly took the time to speak with us on the topic of the debate session she participated in: Should statins be given to people over age 80 for stroke prevention? As co-Chair of CONy 2021, she also shared her excitement for the next congress, which will be […]
Arlene Wilkie, ESO-WSO 2020 – Stroke Action Plan for Europe
We were delighted to have an opportunity to hear all about the Stroke Action Plan for Europe from Arlene Wilkie, Director General of the Stroke Alliance for Europe (SAFE). Related useful resources: Stroke Alliance for Europe (SAFE) Economic Impact of Stroke in Europe Questions What are the major challenges in stroke care across Europe and […]
Patent Foramen Ovale Closure—Addressing the Unmet Need for Reducing the Risk of Ischemic Stroke
US Neurology. 2020;16(1):54–60 DOI: https://doi.org/10.17925/USN.2020.16.1.54
Globally, a high proportion (around 25%) of transient ischemic attacks (TIAs) and ischemic strokes are cryptogenic.1,2 The Trial of ORG 10172 in Acute Stroke Treatment (TOAST) classification defines a cryptogenic stroke as a brain infarction that is not caused by definite cardioembolism, large artery atherosclerosis, or small artery disease, despite extensive investigations.3 The “ASCOD” classification defines strokes […]
Anna Tancin Lambert, EAN 2020 – Atrial Fibrillation and Cryptogenic Stroke in the NOR-FIB Study
Anna Tancin Lambert (University of Oslo and Department of Neurology Østfold Hospital Trust, Norway) discussed with us exciting interim findings from the international, multicentre, prospective, observational Nordic Atrial Fibrillation and Stroke (NOR-FIB) study, which highlight atrial fibrillation as the hidden cause of cryptogenic stroke (ClinicalTrials.gov Identifier: NCT02937077). Questions 1. What proportion of stroke and transient […]
Acute Stroke Imaging in the Era of the DAWN, DEFUSE 3 and WAKE-UP Study Findings
European Neurological Review. 2019:14(1):24–7. DOI: https://doi.org/10.17925/ENR.2019.14.1.24
In 2018, two randomised controlled trials, DAWN (the Clinical Mismatch in the Triage of Wake up and Late Presenting Strokes Undergoing Neurointervention with Trevo Thrombectomy Procedure) and DEFUSE 3 (Endovascular Therapy Following Imaging Evaluation for Ischaemic Stroke 3), implemented computed tomography (CT) and magnetic resonance imaging (MRI) in patients with stroke.1,2 These studies showed the […]
Ulrich Dirnagl, EAN 2019 – Charles Edouard Brown-Séquard Lecture
The Charles Edouard Brown-Séquard Lecture at EAN 2019 was delivered by Prof. Ulrich Dirnagl, who had a chat with EAN eCommunciations Board Co-Chair, PD DR. Tim von Oertzen about his work. Video produced by and shared with kind authorisation of the European Academy of Neurology (EAN 2019).
Jeffrey L Saver & Natan Bornstein, ESOC 2019 – ImpACT-24B
Trial investigators Jeffrey L Saver and Natan Bornstein share results and insights from the Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window (ImpACT-24B; NCT00826059). The aim of this international, randomised, double-blind, sham-controlled, pivotal trial was to determine whether sphenopalatine ganglion stimulation 8-24 h after acute ischaemic stroke improved […]
Nikola Sprigg, ESOC 2019 – TICH-2
Nikola Sprigg, Principal Investigator of the Tranexamic acid for IntraCerebral Haemorrhage 2 (TICH-2) trial (ISRCTN93732214), which previously reported that tranexamic acid does not improve outcome in adults with stroke due to intracerebral haemorrhage despite reducing haematoma expansion, shares results and insights from one-year follow up data. Content produced in Milan, Italy and shared with kind authorisation […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!